Arix Pegs LogicBio's Technology As 'Occam's Razor' Of Gene Therapy

30 Jun 2017

• By Lubna Ahmed

Gene therapy startup LogicBio, with input from Arix Biosciences, has raised almost $50m via a series B financing round; it plans to use the cash to continue development of a potential novel alternative to traditional gene therapy.

LogicBio Therapeutics has raised $45m in a series B financing, led by Arix Biosciences, bringing to $50m the total the recently launched firm has raised to complete preclinical development of an innovative gene therapy platform for pediatric diseases and move lead programs into clinical studies.

Arix's CEO Joe Anderson told Scrip that Arix had "identified limitations with traditional gene therapy and the need for gene...